High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 52, 2011, Pages 21194-21199

  Logan, Aaron C ^a   Gao, Hong ^a   Wang, Chunlin ^a   Sahaf, Bita ^a   Jones, Carol D ^a   Marshall, Eleanor L ^a   Buño, Ismael ^b   Armstrong, Randall ^c   Fire, Andrew Z ^a   Weinberg, Kenneth I ^a   Mindrinos, Michael ^a   Zehnder, James L ^a   Boyd, Scott D ^a   Xiao, Wenzhong ^a,d   Davis, Ronald W ^a   Miklos, David B ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Consensus primed polymerase chain reaction; Immune reconstitution; Next generation sequencing

Indexed keywords

IMMUNOGLOBULIN G;

ALLELE; ARTICLE; BLOOD SAMPLING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE AMPLIFICATION; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN CELL; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOGLOBULIN HEAVY CHAIN GENE; MINIMAL RESIDUAL DISEASE; MOLECULAR CLONING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PYROSEQUENCING;

COMPUTATIONAL BIOLOGY; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; NEOPLASM, RESIDUAL; OLIGONUCLEOTIDES; POLYMERASE CHAIN REACTION; RECURRENCE; SENSITIVITY AND SPECIFICITY; TRANSPLANTATION, HOMOLOGOUS;

EID: 84862961025     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1118357109     Document Type: Article

References (37)

1. National Cancer Institute (2011) SEER Cancer Statistics Review. Available at http://seer.cancer.gov/csr. Accessed May 13, 2011.
2. Hallek M (2009) State-of-the-art treatment of chronic lymphocytic leukemia. Hematology (Am Soc Hematol Educ Program) 2009:440-449.
3. Hallek M, et al.; International Workshop on Chronic Lymphocytic Leukemia (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446-5456.
4. Gribben JG (2010) How I treat CLL up front. Blood 115:187-197.
5. Khouri IF, et al. (2004) Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: Impact of rituximab on immunomodulation and survival. Exp Hematol 32:28-35. (Pubitemid 38064398)
6. Sorror ML, et al. (2005) Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 23:3819-3829.
7. Provan D, et al. (1996) Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 88:2228-2235. (Pubitemid 26307926)
8. Esteve J, et al. (2001) Stem cell transplantation for chronic lymphocytic leukemia: Different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status. Leukemia 15:445-451. (Pubitemid 32243779)
9. Böttcher S, et al. (2004) Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. Leukemia 18:1637-1645. (Pubitemid 39386342)
10. Rawstron AC, de Tute R, Jack AS, Hillmen P (2006) Flow cytometric protein expression profiling as a systematic approach for developing disease-specific assays: Identification of a chronic lymphocytic leukaemia-specific assay for use in rituximab-containing regimens. Leukemia 20:2102-2110. (Pubitemid 44782835)
11. Ritgen M, et al. (2004) Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: Implications of minimal residual disease measurement with quantitative PCR. Blood 104:2600-2602.
12. Moreton P, et al. (2005) Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 23:2971-2979. (Pubitemid 46224116)
13. Farina L, et al. (2009) Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: Early assessment can predict long-term outcome after reduced intensity allogeneic transplantation. Haematologica 94:654-662.
14. van Dongen JJM, et al. (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene Recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17:2257-2317. (Pubitemid 38072572)
15. Boyd SD, et al. (2009) Measurement and clinical monitoring of human lymphocyte clonality by massively parallel V-D-J pyrosequencing. Sci Transl Med 1(12):12ra23.
16. Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW (2007) Characterization of mutation spectra with ultra-deep pyrosequencing: Application to HIV-1 drug resistance. Genome Res 17:1195-1201. (Pubitemid 47204863)
17. Campbell PJ, et al. (2008) Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc Natl Acad Sci USA 105:13081-13086.
18. Brisco MJ, Tan LW, Orsborn AM, Morley AA (1990) Development of a highly sensitive assay, based on the polymerase chain reaction, for rare B-lymphocyte clones in a polyclonal population. Br J Haematol 75:163-167. (Pubitemid 20185452)
19. Sioutos N, et al. (1995) Polymerase chain reaction versus Southern blot hybridization. Detection of immunoglobulin heavy-chain gene rearrangements. Diagn Mol Pathol 4:8-13.
20. Magnac C, et al. (1999) Detection of minimal residual disease in B chronic lymphocytic leukemia (CLL). Hematol Cell Ther 41:13-18. (Pubitemid 29111279)
21. Böttcher S, et al. (2009) Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: A comparative analysis. Leukemia 23:2007-2017.
22. Pollard P, Owen G, Worwood M (1993) PCR-based immunogenotyping at the Ig heavy chain CDR3 locus: Improvements in resolution. Br J Haematol 84:169-171. (Pubitemid 23158134)
23. Nguyen P, et al. (2011) Identification of errors introduced during high throughput sequencing of the T cell receptor repertoire. BMC Genomics 12:106.
24. Dreger P, Ritgen M, Böttcher S, Schmitz N, Kneba M (2005) The prognostic impact of minimal residual disease assessment after stem cell transplantation for chronic lymphocytic leukemia: Is achievement of molecular remission worthwhile? Leukemia 19:1135-1138. (Pubitemid 40945994)
25. Ritgen M, et al.; German CLL Study Group (2008) Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: Results from the GCLLSG CLL3X trial. Leukemia 22: 1377-1386. (Pubitemid 352006082)
26. Böttcher S, Ritgen M, Dreger P (2011) Allogeneic stem cell transplantation for chronic lymphocytic leukemia: Lessons to be learned from minimal residual disease studies. Blood Rev 25:91-96.
27. Sarantopoulos S, et al. (2011) Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. Blood 117:2275-2283.
28. Arai S, et al. (2008) Prophylactic Rituximab after reduced intensity conditioning transplantation results in low chronic GVHD. Blood 112:466.
29. Itälä M, et al. (2008) Stem cell transplantation in poor-risk chronic lymphocytic leukemia: assessment of post-transplant minimal residual disease using four- and sixcolor flow cytometry and allele-specific RQ-PCR. Eur J Haematol 81:100-106. (Pubitemid 352019629)
30. Nabhan C, Coutré S, Hillmen P (2007) Minimal residual disease in chronic lymphocytic leukaemia: Is it ready for primetime? Br J Haematol 136:379-392. (Pubitemid 46046296)
31. Moreno C, Ritgen M, Rawstron A (2010) Is MRD eradication a desirable goal in CLL? Best Pract Res Clin Haematol 23:97-107.
32. Varghese AM, Rawstron AC, Hillmen P (2010) Eradicating minimal residual disease in chronic lymphocytic leukemia: Should this be the goal of treatment? Curr Hematol Malig Rep 5:35-44.
33. Lowsky R, et al. (2005) Protective conditioning for acute graft-versus-host disease. N Engl J Med 353:1321-1331. (Pubitemid 41362700)
34. Kohrt HE, et al. (2009) TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood 114:1099-1109.
35. Ladetto M, et al. (2000) Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma. Biol Blood Marrow Transplant 6:241-253.
36. Margulies M, et al. (2005) Genome sequencing in microfabricated high-density picolitre reactors. Nature 437:376-380. (Pubitemid 41613494)
37. Giudicelli V, Chaume D, Lefranc MP (2005) IMGT/GENE-DB: A comprehensive database for human and mouse immunoglobulin and T cell receptor genes. Nucleic Acids Res 33(Database issue):D256-D261. (Pubitemid 40207873)